glp-1 discontinuation rates Proportion of Patients Who Discontinued RA Therapy, n=4791 GLP-1 Agonists For Obesity In

Dr Lauren Struszczak joins the Healthcare Today Podcast to talk about why nutrition is central to supporting patients on weight-loss medications.

HOW TO SUBMIT 1

With semaglutide patent expiry expected next year, competitive entry could pull prices down from current ~1726k/month and accelerate adoption

Three GLP-1 compounds, three vial sizes, one bac water ratio that works

We also review the current state-of-knowledge as to how inhaled cannabis/cannabinoids can shape immune response in the lungs and discuss the potential consequences of altered pulmonary immunity

With the successive launch of Glucagon-like peptide-1 (GLP-1) class drugs that allow weight loss with a once-daily pill instead of an injection, the barrier to obesity treatment is lowering